The use of glucocorticoids in marmoset wasting syndrome

Pete Otovic, Shanequa Smith, Eric Hutchinson

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation. Method: Eleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8 weeks. Results: The marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy. Conclusions: Glucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalJournal of medical primatology
Volume44
Issue number2
DOIs
StatePublished - Apr 1 2015

Keywords

  • Callitrichid
  • Corticosteroids
  • Inflammatory bowel disease
  • Monkey

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Fingerprint Dive into the research topics of 'The use of glucocorticoids in marmoset wasting syndrome'. Together they form a unique fingerprint.

Cite this